migores1

RNAC Share Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024

VaselineAugust 8, 2024

0 1 minute read

RNAC Share Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024

RNAC Stock - RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024

Source: iQoncept / Shutterstock

Cartesian therapeutics (NASDAQ:RNAC) just reported results for the second quarter of 2024.

Cartesian Therapeutics reported earnings per share of 54 cents. This was above the analyst estimate for EPS of -$1.19.
The company reported revenue of $33.45 million.
This was 1,727.60% better than the analyst estimate for revenue of $1.83 million.

InvestorPlace Earnings is a project that uses data from TradeSmith to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways, including earnings per share and revenue, as well as how a company measures up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers about the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at [email protected].

Print article from InvestorPlace Media, https://investorplace.com/earning-results/2024/08/rnac-stock-earnings-cartesian-therapeutics-for-q2-of-2024/.

VaselineAugust 8, 2024

0 1 minute read

Vaseline

Related Articles

Sibanye Stillwater Limited (SBSW) Q2 2024 Earnings Call Transcript

Athabasca Oil: Big improvement, but still risky

Dow Jones sets new record high before retreating on Friday

Two-thirds of institutional Bitcoin ETF holders held or bought more in Q2